US EditionPublished • loading... • Updated
E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves
Summary by Intelligence360 News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
E2 (Endovascular Engineering) Raises $80 Million Series C to Advance Next-Generation Thrombectomy Platform as Pulmonary Embolism Treatment Evolves
Gilde Healthcare and Norwest co-led round to commercialize the Hēlo® Thrombectomy Platform MENLO PARK, Calif., April 7, 2026 /PRNewswire/ — Endovascular Engineering, Inc. (“E2”), a commercial-stage medical technology company focused on advancing the treatment of venous thromboembolism (VTE), today announced an oversubscribed $80 million Series C financing co-led by Gilde Healthcare and Norwest, with participation from existing investors includin…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
